Paolo Marchetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study	THE ONCOLOGIST	2024
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis	BMC CANCER	2024
Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis	BMC CANCER	2024
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience	BMC CANCER	2024
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2023
The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management	FRONTIERS IN ONCOLOGY	2023
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer	CLINICAL CANCER RESEARCH	2023
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma	CANCERS	2023
Circulating CD137 + T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients	CLINICAL CANCER RESEARCH	2022
Angiogenic factors as prognostic markers in neuroendocrine neoplasms	ENDOCRINE	2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	JOURNAL OF HEMATOLOGY & ONCOLOGY	2022
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response	EBIOMEDICINE	2022
The potential role of genomic signature in stage II relapsed colorectal cancer (CRC) patients: a mono-institutional study	CANCER MANAGEMENT AND RESEARCH	2022
A 17-gene expression signature for early identification of poor prognosis in clear cell renal cell carcinoma	CANCERS	2022
Immunotherapy and chemo-immunotherapy for non–small cell lung cancer with novel actionable oncogenic driver alterations.	JOURNAL OF CLINICAL ONCOLOGY	2022
Patients' Satisfaction with Breakthrough Cancer Pain Therapy. A Secondary Analysis of IOPS-MS Study	CANCER MANAGEMENT AND RESEARCH	2022
Genomic and immune approach in platinum refractory HPV-negative head and neck squamous cell carcinoma patients treated with Immunotherapy: a novel combined profile	BIOMEDICINES	2022
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations	ANNALS OF ONCOLOGY	2022
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients	ANNALS OF ONCOLOGY	2022
EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy	JOURNAL OF THORACIC ONCOLOGY	2022

1
2
3
4
5
6
7
8
9
10
11
12
seguente ›
ultima »